Skip to main navigation

Top Bar Nav

Contact Us

Social Icons

linkedin twitter

About Nav

About

Pioneering Pathways

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories

Our Stories

News Nav

News

IR Nav

Investors

Careers Nav

Careers

Home News Press Release Archive

Press Release Archive

News Nav

News
Press Release Archive
Events Archive
Our Stories

Media Contact

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc

Send Email
Ireland: +353 1 637 2141
US: 215-867-4948

Press Release Archive

Year

Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

July 22, 2025

Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

July 10, 2025

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

July 1, 2025

Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

June 10, 2025

Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

June 9, 2025

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

June 2, 2025

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

June 2, 2025

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

May 29, 2025

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

May 21, 2025

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

May 6, 2025

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Displaying 31 - 40 of 607

About Nav

About

Pioneering Pathways Nav

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories Nav

Our Stories

News Nav

News

Careers Nav

Careers

IR Nav

Investors

© 2026 Jazz Pharmaceuticals plc All Rights Reserved.

Legal Nav

Privacy Statement
U.S. Consumer Health Data Privacy Policy
Terms of Use
Social Media Global Guidelines
Your Privacy Choices
Sitemap